Abstract
The requirements for effective cancer vaccines have gradually been worked out in experimental models over the past 15 years [1–3]. Many clinical trials in this field were initiated before this information was available or did not adhere to the methodologic requirements that had been found in the animal studies. As a consequence, there are several negative clinical investigations of active specific immunotherapy in which failure was a virtual certainty [4–6] when looked at in retrospect with regard to the requirements that have been identified in animal models. Some of the key requirements are as follows.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bartiett GL, Zbar B (1972) Tumor-specific vaccine containing mycobacterium bovis and tumor cells: safety and efficacy. J Natl Cancer Inst 48: 1709–1726
Scott MT (1975) Potentiation of the tumor–specific immune response by Corynebacterium parvum. J Natl Can Inst 55: 65–72
Hanna MG, Peters LC (1981) Morphological and functional aspects of active specific immunotherapy of established pulmonary metastases in guinea pigs. Cancer Res 41: 4001–4009
Hudson CN, McHardy JE, Curling OM etal. (1976) Active specific immunotherapy for ovarian cancer. Lancet 7991: 877–879
Newlands ES, Oon CJ, Roberts JT etal. (1976) Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma. Br J Cancer 34: 174–179
Gray BN, Walker C, Andrewartha L etal. (1988) Melbourne trial of adjuvant immunotherapy in operable large bowel cancer. Aust NZ J Surg 58: 43–46
Tykka H, Oravisto KJ, Lehtonen T etal. (1978) Active specific immunotherapy of advanced renal-cell carcinoma. Eur Urol 4: 250–258
McCune CS, Schapira DV, Henshaw EC (1981) Specific immunotherapy of advanced renal carcinoma: evidence for the polyclonality of metastases. Cancer 47: 1984–1987
Sahasrabudhe DM, deKernion JB, Pontes JE etal. (1986) Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J Biol Resp Mod 5: 581–594
Neidhart JA, Gagen M, Young D, Wise H (1983) A randomized study of polymerized tumor antigen admixed with adjuvant for therapy of renal cancer. Proc Am Soc Clin Oncol 2: 49
Adler A, Gillon G, Lurie H etal. (1987) Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormone-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects. J Biol Resp Mod 6: 610–624
Scharfe T, Muller S, Riedmiller H etal. (1989) Immunotherapy of metastasizing renal cell carcinoma. Urol Int 44: 1–4
Hoover HC, Surdyke M, Dangel RB etal. (1984) Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guerin vaccine. Cancer Res 44: 1671–1676
Hoover HC, Surdyke MG, Dangel RB etal. (1985) Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 55: 1236–1243
Berd D, Maguire HC, Mastrangelo MJ (1986) Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46: 2572–2577
Mitchell MS, Kan-Mitchell J, Kempf RA etal. (1988) Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 48: 5883–5893
McCune CS, Marquis DM (1990) Interleukin-1 as an adjuvant for active specific immunotherapy in a murine tumor model. Cancer Res 50: 1212–1215
Law LS (1980) Changes in tumor-specific antigen expression during passage in vitro and in vivo of newly derived methylcholanthrene-induced sarcomas of Balb/C mice. Int J Cancer 25: 251–259
Economou GC, Takeichi N, Boone CW (1977) Common tumor rejection antigens in methylcholanthrene-induced squamous cell carcinomas of mice detected by tumor protection and a radioisotopic footpad assay. Cancer Res 37: 37–41
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
McCune, C.S. (1991). Active Specific Immunotherapy in Renal Cell Carcinoma: Optimization. In: Debruyne, F.M.J., Bukowski, R.M., Pontes, J.E., de Mulder, P.H.M. (eds) Immunotherapy of Renal Cell Carcinoma. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75853-9_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-75853-9_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-52835-7
Online ISBN: 978-3-642-75853-9
eBook Packages: Springer Book Archive